ClinGuide CRISPR sgRNA
Oligonucleotide GMP manufacturing for human therapeutics
Receive your quote directly from the manufacturer.
Agilent provides cGMP-compliant manufacturing services for single-guide RNA used in human therapeutics, offering high-purity, scalable, and regulatory-ready solutions to support clinical gene editing programs.
How to obtain high-purity sgRNAs for compliant CRISPR/Cas genome editing
Wednesday, June 25, 2025 at 16:00 BST / 17:00 CEST / 11:00 EDT / 8:00 PDT
CRISPR single guide RNAs (sgRNAs) are essential components of the CRISPR-Cas9 gene-editing system, serving as the navigational tool that directs the Cas9 enzyme to a specific target sequence in the genome. Each sgRNA is a short synthetic RNA composed of a scaffold sequence that binds to Cas9 and a custom-designed spacer sequence that defines the DNA target.
The accuracy and effectiveness of CRISPR-based editing depend heavily on the quality and integrity of the sgRNA. High-purity, full-length sgRNAs are crucial for minimizing off-target effects and ensuring consistent performance, particularly in clinical and Good Manufacturing Practice (GMP) settings where regulatory standards, such as those outlined by the FDA, demand rigorous quality control.
This webinar outlines a GMP-validated technique for purifying CRISPR sgRNAs that ensures over 80% full-length purity, as verified by high-resolution HPLC methods, and complies with the latest FDA standards.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
